MedTrace Logo

18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma

NCT01610544 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-07-05

No results posted yet for this study

Summary

Background:

\- Imaging studies like positron emission tomography (PET) and computed tomography (CT) scans are used to detect tumor responses to cancer treatment. However, it may be difficult to detect early response to lung cancer or thymoma treatment with standard PET/CT scans. These scans cannot easily show a difference between remaining cancer cells and inflammation. Researchers want to try a new PET/CT scan tracer that may be able to show the difference between these cells. 18F-Fluorothymidine (18F-FLT) is better at showing which cells are still actively dividing. PET/CT scans with 18F-FLT may help show if tumor cells are responding to early stages of treatment.

Objectives:

\- To see if 18F-FLT is a safe and effective imaging study tracer to show early cancer response to treatment.

Eligibility:

\- Individuals at least 18 years of age who are being treated for lung cancer or thymoma.

Design:

* Participants will be screened with a physical exam and medical history. Blood, urine, and tumor tissue samples will be collected.
* Participants will have two PET/CT scans on separate days before starting chemotherapy. One scan will be with a standard radiotracer. The other will be with the 18F-FLT tracer.
* About 2 weeks after starting chemotherapy, participants will repeat the two PET/CT scans on separate days. Additional blood samples will be collected at this time.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Thymus Neoplasms

Interventions

DRUG

3'-deoxy-3'-18F fluorothymidine (FLT)

OTHER

PET/CT scan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Maria Liza Lindenberg, M.D. · National Cancer Institute (NCI)

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-10
Primary Completion
2012-12-10
Completion
2012-12-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01610544 on ClinicalTrials.gov